It was noted that the production of inflammatory cytokines was decreased after a study done with sepsis on mouse. The reason for this is because of fluvoxamine that binds in immune cells, specifically to the sigma-1 receptor. A decrease of the expression of inflammatory genes was also noted after an in vitro study took place. It was found that fluvoxamine caused this decrease. To determine if the anti-inflammatory effects of fluvoxamine detected do occur in humans and are applicable in COVID-19 there needs to be more investigation and studies (National Institutes of Health, 2021).

National Institutes of Health. 2021. Fluvoxamine: Anti-Inflammatory Effects of Fluvoxamine and Rationale for Use in COVID-19. https://www.covid19treatmentguidelines.nih.gov/therapies/immunomodulators/fluvoxamine/  Date of access: 27 Oct. 2021